1-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-phenylpyrimidine-2,4-dione | 76756-28-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-phenylpyrimidine-2,4-dione
• CAS: 76756-28-0
• 化学式: C₁₅H₁₆N₂O₅
• 分子量: 304.3
• InChiKey: GLRAEFXZTFJYRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIE
  申请人：SPEROVIE BIOSCIENCES INC

  公开号：WO2018013908A1

  公开（公告）日：2018-01-18

  This invention relates to compounds and compositions for the induction of expression of a pattern recognition receptor (e.g., STING) and methods of use thereof.

  这项发明涉及用于诱导模式识别受体（例如STING）表达的化合物和组合物，以及其使用方法。
• Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
  申请人：Schinazi Raymond F.

  公开号：US20100168052A1

  公开（公告）日：2010-07-01

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  本发明提供了一种用于治疗、预防和/或预防宿主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药物接受者中给予有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地在药学上可接受的稀释剂或赋形剂中。
• TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD PHARMASSET LLC

  公开号：US20140336143A1

  公开（公告）日：2014-11-13

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供一种用于治疗、预防和/或预防寄主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药学上可接受的稀释剂或赋形剂中投与有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药。
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
  申请人：Sperovie Biosciences, Inc.

  公开号：US20190292215A1

  公开（公告）日：2019-09-26

  Disclosed are compounds and compositions for the induction of expression of a pattern recognition receptor (e.g., STING) and methods of use thereof.
• US7211570B2
  申请人：——

  公开号：US7211570B2

  公开（公告）日：2007-05-01